Unicorn Capital Partners

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Tezign is a leading enterprise content and AI company founded in 2015, specializing in generative AI solutions for content creation and management. The company focuses on building a digital infrastructure that enhances the efficiency and quality of content production for global enterprises. Tezign has partnered with over 200 notable companies, including major brands like Alibaba, Unilever, and Procter & Gamble, and has successfully generated more than 150,000 content assets. Its platform employs advanced data technology and image recognition to connect top designers with businesses, facilitating marketing content production and optimization. Additionally, Tezign has cultivated a content ecosystem comprising over 100,000 content creators, establishing a significant scale in content asset management.

Botkin.AI is a healthcare technology company based in Moscow, founded in 2015, specializing in medical image processing and analysis through artificial intelligence. The company's platform utilizes deep machine learning to analyze radiograms and assess the risk of tumors, enhancing the diagnostic capabilities of radiologists. By enabling the accurate early detection of oncological diseases, particularly lung cancer, Botkin.AI facilitates a faster processing of clinical data while maintaining high-quality medical conclusions. This innovative approach aims to improve the overall efficiency and effectiveness of healthcare providers in diagnosing critical conditions.